Moss, 16 December 2024
 
Reference is made to the annual general meeting 29 April 2024 where guidelines for remuneration of executive personnel were approved. In accordance with these guidelines the board of Gentian Diagnostics ASA has allocated a total of 295,000 options to key employees under the existing option program. 

The following number of options have been allocated to Matti Heinonen, Chief Executive Officer of Gentian Diagnostics ASA: 100,000 options. Following the allocation Mr. Heinonen holds 100,000 options in the Company.

For Mr Heinonen, the right to exercise the options is vested over a period of 2 years, with 50% of the options vesting by the end of each year as follows: (i) 50% of the options granted, no earlier than 3 years after the allocation date at an exercise price of NOK 62.61 per share,  (ii) 50% of the options granted, no earlier than 4 years after the allocation date at an exercise price of NOK 64.80 per share. The options may also be exercised at expiry after 5 years at an exercise price of NOK 67.07 per share. 

The following number of options have been allocated to other primary insiders of Gentian Diagnostics ASA:
 
Frank Frantzen, Chief Technology Officer: 50,000 options. Following the allocation Mr. Frantzen holds 20,000 shares and 50,000 options in the Company.

Njaal Kind, Group Chief Financial Officer: 40,000 options. Following the allocation Mr. Kind holds 26,125 shares and 180,670 options in the Company.
 
Markus Jaquemar, Chief Commercial Officer: 40,000 options. Following the allocation Mr. Jaquemar holds 127,500 options in the Company.

Aleksandra Havelka, Chief Scientific Officer: 20,000 options. Following the allocation Ms. Havelka hold 2,000 shares and 80,000 options in the Company. 

Torsten Knüttel, Vice President R&D: 10,000 options. Following the allocation Mr. Knüttel holds 1,125 shares and 70,000 options in the Company. 

For the individuals listed above, the following applies: The basis for the exercise price for the options granted is the volume weighted average price on the Oslo Stock Exchange for the past 10 trading days prior 22 November 2024. The right to exercise the options is vested over a period of 2 years, with 50% of the options vesting by the end of each year as follows: (i) 50% of the options granted, no earlier than 3 years after the allocation date at an exercise price of NOK 45.79 per share,  (ii) 50% of the options granted, no earlier than 4 years after the allocation date at an exercise price of NOK 47.39 per share. The options may also be exercised at expiry after 5 years at an exercise price of NOK 49.05 per share. 

Attached are the notifications of the transactions pursuant to the market abuse regulation article 19. 
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

For further information, please contact:
Njaal Kind
CFO, Gentian Diagnostics ASA
E-mail: njaal.kind@gentian.no 
Phone. +47 919 06 525
